NASDAQ
STAA
Last Price
US $25.33
KEY FIGURES
MKT CAP
$1.3B
EPS
TTM
$0.08
EPS Growth (1Y)
295.12%
PEG
TTM
-
P/E
TTM
-
P/S
TTM
3.75x
YIELD
-
GROWTH (5Y CAGR)
Revenue
Valuation
Financial
Performance
Cash flow to debt coverage
STAAR Surgical Company cash flow to debt ratio of -89.25% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Free cash flow growth
STAAR Surgical Company has insufficient data to evaluate this check.
Debt-to-equity ratio
STAAR Surgical Company's debt to equity ratio is 0.11, which means that the company's assets are healthy financed, signaling financial stability.
Debt-to-equity trend
STAAR Surgical Company has insufficient data to evaluate this check.
Net debt to EBITDA
STAAR Surgical Company has a net cash position, so leverage is healthy.
Interest coverage
STAAR Surgical Company earns at least as much interest as it pays. Interest obligations are fully covered.
Profit margin growth
STAAR Surgical Company's profit margin has decreased (12.50%) in the last year from -6.44% to -7.24%, signaling decreasing performance
Current ratio
STAAR Surgical Company's short-term assets of $311.55M exceed its short-term liabilities of $68.50M
Return on assets
STAAR Surgical Company's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Return on equity
STAAR Surgical Company's return on equity of -6.07%, is lower than 15.00%, indicating bad performance
Earnings quality
STAAR Surgical Company's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Earnings stability
STAAR Surgical Company had positive net income in 3 out of 5 years, indicating stable and consistent earnings
Positive free cash flow
STAAR Surgical Company has negative free cash flow, indicating the company is burning cash rather than generating it
Free cash flow yield
STAAR Surgical Company has negative free cash flow, indicating cash burn
Earnings growth
STAAR Surgical Company's yearly earnings has decreased 298.10% since last year from $-20.21M to $-80.45M, signaling decreasing performance
Revenue growth
STAAR Surgical Company has insufficient data to evaluate this check.
Return on invested capital
ROIC -1.26% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
3-year revenue CAGR
STAAR Surgical Company's 3-year revenue CAGR of -5.57% is negative, indicating declining revenue over the past 3 years
Revenue consistency
STAAR Surgical Company had revenue growth in 3 out of 5 years, indicating consistent revenue performance
Return on equity consistency
STAAR Surgical Company has insufficient net-income and equity history to evaluate ROE consistency.
Cash Flow Valuation (DCF)
STAAR Surgical Company has insufficient data to evaluate this check.
Earnings yield (TTM)
STAAR Surgical Company has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
EBITDA Valuation
STAAR Surgical Company is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
EV/EBITDA (FY)
STAAR Surgical Company has negative or missing EBITDA, making EV/EBITDA ratio unreliable
PEG ratio (TTM/FY)
STAAR Surgical Company has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Price-to-book ratio (FY)
STAAR Surgical Company has a price-to-book ratio of 3.56x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Price-to-sales ratio (TTM)
STAAR Surgical Company has a price-to-sales ratio of 4.32x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue
Profit margin
Current Ratio
Capital Returns
1.08%
Return on equity
ROIC: 1.90%
Valuation History
316.6X
Price to Earnings
EV/EBITDA: 35.8X
Cash flow
Profit margin
7.93%
EBITDA
-
Cash flow
-
Cash Flow (DCF)
Fair Value
Market $25.33
—
Default assumptions
EBITDA Multiple
Fair Value
Market $25.33
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.